Table 2 Clinical parameters and association with AKT1 E17K mutation in previously untreated breast cancer patients (cohort A)
Parameter | Total (N = 494) | Mutation | P-valuea (adjusted P-value) | |
|---|---|---|---|---|
Wild type (n = 465) | AKT1 E17K (n = 29) | |||
Age, years | 0.55 (1.00) | |||
< 35 | 8 (1.6) | 8 (1.7) | 0 | |
35–65 | 255 (51.6) | 241 (51.8) | 14 (48.3) | |
> 65 | 231 (46.8) | 216 (46.5) | 15 (51.7) | |
Menopausal statusb | 0.34 (1.00) | |||
Pre | 77 (15.6) | 74 (15.9) | 3 (10.3) | |
Post | 381 (77.1) | 356 (76.6) | 25 (86.2) | |
UICC stage | 0.04 (0.47) | |||
I | 142 (28.7) | 129 (27.7) | 13 (44.8) | |
II | 198 (40.1) | 187 (40.2) | 11 (37.9) | |
III | 110 (22.3) | 105 (22.6) | 5 (17.2) | |
IV | 44 (8.9) | 44 (9.5) | 0 | |
Grade | 0.03 (0.38) | |||
1 | 72 (14.6) | 64 (13.8) | 8 (27.6) | |
2 | 315 (63.8) | 296 (63.7) | 19 (65.5) | |
3 | 107 (21.7) | 105 (22.6) | 2 (6.9) | |
Lymph-node metastasis (N stage)c | 0.17 (1.00) | |||
N0 | 238 (48.2) | 223 (48.0) | 15 (51.7) | |
N1 | 138 (27.9) | 128 (27.5) | 10 (34.5) | |
N2 | 78 (15.8) | 77 (16.6) | 1 (3.4) | |
N3 | 39 (7.9) | 36 (7.7) | 3 (10.3) | |
Distant metastasis (M stage) | 0.02 (0.25) | |||
M0 | 450 (91.1) | 421 (90.5) | 29 (100) | |
M1 | 44 (8.9) | 44 (9.5) | 0 | |
Histologyd | 0.83 (1.00) | |||
Ductal | 368 (74.5) | 346 (74.4) | 22 (75.9) | |
Lobular | 89 (18.0) | 85 (18.3) | 4 (13.8) | |
Mixed | 10 (2.0) | 9 (1.9) | 1 (3.4) | |
Others | 23 (4.7) | 21 (4.5) | 2 (6.9) | |
St. Gallen criteriae | 0.19 (1.00) | |||
Luminal A | 210 (42.5) | 194 (41.7) | 16 (55.2) | |
Luminal B1 | 53 (10.7) | 52 (11.2) | 1 (3.4) | |
Luminal B2 | 231 (46.8) | 219 (47.1) | 12 (41.4) | |
HER2 status | 0.03 (0.38) | |||
IHC-Score (3+) | 37 (7.5) | 37 (8.0) | 0 | |
IHC-Score (0 - 2+) | 457 (92.5) | 428 (92.0) | 29 (100) | |
PR statusf | 0.91 (1.00) | |||
Negative | 43 (8.7) | 41 (8.8) | 2 (6.9) | |
Positive | 375 (75.9) | 356 (76.6) | 19 (65.5) | |